Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Elan, Proteostasis Ink Research Agreement

by Rick Mullin
June 6, 2011 | A version of this story appeared in Volume 89, Issue 23

Elan and Proteostasis Therapeutics are joining to advance Proteostasis’ technology for the discovery and development of small-molecule drugs and diagnostics that treat neurodegenerative disorders such as Parkinson’s disease and dementia-related diseases including Alzheimer’s. The partners will work on targets and compounds that modulate proteostasis network pathways. Elan will spend $20 million for a 24% stake in Proteostasis. It may provide up to $30 million more in funding and will have right of first negotiation for licensing compounds rising from the collaboration.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.